Intismeran autogene

Phase 3Biologic

Intismeran autogene is one of 179 biologic programs targeting Non-Small Cell Lung Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

178

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CarcinomaRecruiting

Malignant MelanomaRecruiting

MelanomaActive, not recruiting

Bladder CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Cutaneous Squamous Cell CarcinomaActive, not recruiting

Non-Small Cell Lung CarcinomaPhase 2

Recruiting

Malignant MelanomaPhase 2

Recruiting

MelanomaPhase 3

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Cutaneous Squamous Cell CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

191 competitors in Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

95 2

Opdivo

Mekinist

45 4

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 3

39 5

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

35 6

Taxol

Teva

Phase 3

13 7

Tecentriq

Roche

Phase 3

11 8

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

28 9

Lenvima

Eisai

Phase 3

9 10

Intron a

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Active, not recruiting

Melanoma

NCT05933577

Q2 2031

Phase 2Recruiting

Non-Small Cell Lung Carcinoma

NCT07221474

Q3 2031

Phase 2Recruiting

Urinary Bladder Neoplasms

NCT06833073

Phase 2Recruiting

Malignant Melanoma

NCT06961006

Q4 2031

Phase 1/2Active, not recruiting

Bladder Cancer

NCT06305767

Clinical

Trials by Indication[1]

Bladder Cancer1 trial

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06305767·230 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2/3·NCT06295809·46 enrolled

Melanoma1 trial

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05933577·1,089 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06077760·868 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06623422·680 enrolled

4 more indications

Urinary Bladder Neoplasms1 trial

A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06833073·308 enrolled

Non-Small Cell Lung Carcinoma1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07221474·180 enrolled

Renal Cell Carcinoma1 trial

A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06307431·272 enrolled

Malignant Melanoma1 trial

A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06961006·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Intismeran autogene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intismeran autogene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intismeran autogene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Intismeran autogene

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q2 2031

Q3 2031

Q4 2031

Trials by Indication[1]

Bladder Cancer1 trial

Cutaneous Squamous Cell Carcinoma1 trial

Melanoma1 trial

Non-Small Cell Lung Cancer1 trial

Carcinoma, Non-Small-Cell Lung1 trial

Urinary Bladder Neoplasms1 trial

Non-Small Cell Lung Carcinoma1 trial

Renal Cell Carcinoma1 trial

Malignant Melanoma1 trial

References

Drug Info

Quick Facts

Related News